glp-1 gastric intestinal obstruction class action in michigan gi Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research Patients claim blindness, bowel injuries

Unlike older therapies that target one or two receptors, Retatrutide activates three receptors: GLP-1, GIP, and glucagon

Lori Martin

More than half of all adults receiving orforglipron, regardless of dose, achieved an HbA1c of 6.5% or less, and 28.1% of those in the 36 mg orforglipron group achieved an HbA1c of less than 5.7%

was supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants (P30 DK040561, U24 DK132733, and UE5 DK137285)

Many candidates also experience persistent cravings, insulin resistance, or metabolic slowing, which may be addressed by GLP-1 therapy